Slide 1: First Quarter 2023 Financial Results and Business Update
First Quarter 2023 Financial Results and Business Update May 4, 2023
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter
Slide 3: Continued Progress Across Business
Continued Progress Across Business Reaching More gMG Patients Broaden Immunology Pipeline Geographic Expansion $218M in global product revenues in first quarter 2023 5 Global VYVGART Approvals US, Japan, EU, UK and Israel Planned SC Approval June 20th PDUFA Date Five Data Readouts CIDP, ITP, PV, POT
Slide 4: Redefining What 'Well-Controlled' Means for the Patient
Redefining What ‘Well-Controlled’ Means for the Patient Achieve minimal symptom expression Reduce reliance on broad immunosuppressants Regain control of their lives, including professionally and socially Minimize treatment burden We want to transform gMG treatment for patients 4
Slide 5: Steady Cadence of Upcoming Data Readouts
CIDP 16K BP* 52K PC-POTS >500K Steady Cadence of Upcoming Data Readouts 2023 DATA READOUTS Mid-2023 Fourth Quarter 2023 Myositis* 63K Pemphigus 19K ITP 57K ARGX-117 Patient numbers are U.S. prevalence from argenx market research *GO/NO GO Decisions. 2024 DATA READOUTS 2024 MMN 6K Efgartigimod clinic
Slide 6: ARGX-117: First Clinical Efficacy Data Expected Mid-2023
ARGX-117: First Clinical Efficacy Data Expected Mid-2023 MMN: Interim Phase 2 Data Expected Mid-2023 2024 DATA READOUTS ARGX-117: Sweeping Antibody Broaden immunology pipeline clinical Confirm safety profile in MMN patients Measure extent of complement blockade with initial dose scheme Build PK/PD m
Slide 7: ARGX-119: MuSK Agonist with Broad Potential in Neuromuscular Disease
ARGX-119: MuSK Agonist with Broad Potential in Neuromuscular Disease 10 dose cohorts 3 dose cohorts/4 weekly doses Congenital Myasthenic Syndrome (CMS) First-in-Patient Single Ascending Dose Multiple Ascending Dose First-in-patient trial in CMS to serve as proof of biology Translational work ongoing
Slide 8: First Quarter 2023 Revenue Update
75 131 173 218 (in millions of $) Q1 2023 Q4 2022 QoQ % Growth* US 196 159 23% Japan 10 8 16% Europe 10 5 82% Other** 2 1 168% Total 218 173 25% $218M Total Q1 2023 Product Net Sales 2023 DATA READOUTS Breakdown by Region * QoQ growth % reflects operational growth, excluding any impact from changes
Slide 9: First Quarter 2023 Financial Results
First Quarter 2023 Financial Results Three months ended March 31 (in millions of $) 2023 2022 Product net sales 218 21 Collaboration revenue and other 12 10 Total operating income 230 31 Cost of sales (18) (1) R&D expenses (166) (152) SG&A expenses (149) (101) Total operating expenses (334) (254) Op
Slide 10: Transforming the lives of patients with severe autoimmune disease
Humility Innovation Excellence We are on a Co-Creation Empowerment bold mission Transforming the lives of patients with severe autoimmune disease through immunology innovation 10
Slide 11: Optimizing Core Launch Strategies
Payors Optimizing Core Launch Strategies Driving physicians to prescribe in earlier line therapies VYVGART launched in US, Japan and Germany Broadest offering to gMG community, providing more choice to patients 11 Early engagement with payors to enable access for patients SUBMISSIONS IN 10+ COUNTRIE
Slide 12: Global gMG Launch Progressing
Global gMG Launch Progressing 12 United States Global VYVGART Approved December 2021 SC Efgartigimod PDUFA June 20, 2023 Japan Approved January 2022 Europe Approved September 2022 China (Zai Lab) Expected approval in 2023 Canada Expected approval in 2023 United Kingdom Approved March 2023 Israel (Me
Slide 13: argenx 2025: A Leading, Sustainable Immunology Company
Lead with Compassion for our Patients Drive Impact Through Innovation Pioneer with Our Science Build the Company We Want to Work For argenx 2025: A Leading, Sustainable Immunology Company …and gMG is just the beginning 13